Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998;77(1):131–138. doi: 10.1038/bjc.1998.21

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection.

L Biassoni 1, M Granowska 1, M J Carroll 1, S J Mather 1, R Howell 1, D Ellison 1, F A MacNeill 1, C A Wells 1, R Carpenter 1, K E Britton 1
PMCID: PMC2151258  PMID: 9459158

Abstract

The extent of primary surgery for breast cancer could be tailored to the patient if previous information on the presence or absence of lymph node involvement could be reliably determined. Prospective radioimmunoscintigraphy in 29 patients with primary breast cancer that was found on screening has been undertaken with 555 MBq (15 mCi) 99mTc SM3, an Imperial Cancer Research Fund (ICRF) murine monoclonal antibody, 0.5 mg with images at 10 min and 22 h, and analysis using a change detection algorithm. Sites of significant change between the early and later images were displayed as a map of probabilities. Image-positive and -negative axillary lymph nodes were compared by histology in the 28 evaluable patients. The correct identification of the presence or absence of node involvement, even if impalpable, has been shown in 24 out of 28 patients (29 lymph node groups). Sensitivity was 90% (nine out of ten), specificity 84% (16 out of 19) and accuracy 86%. These results encourage further assessment of this technique.

Full text

PDF
131

Images in this article

134Figure 1
on p.134
135Figure 2
on p.135

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler L. P., Crowe J. P., al-Kaisi N. K., Sunshine J. L. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993 Jun;187(3):743–750. doi: 10.1148/radiology.187.3.8497624. [DOI] [PubMed] [Google Scholar]
  2. Bischof-Delaloye A., Delaloye B., Buchegger F., Gilgien W., Studer A., Curchod S., Givel J. C., Mosimann F., Pettavel J., Mach J. P. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med. 1989 Oct;30(10):1646–1656. [PubMed] [Google Scholar]
  3. Britton K. E., Granowska M. The present and future of radiolabelled antibodies in oncology. Ann Nucl Med. 1993 Aug;7(3):127–132. doi: 10.1007/BF03164955. [DOI] [PubMed] [Google Scholar]
  4. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987 Oct 15;47(20):5476–5482. [PubMed] [Google Scholar]
  5. Burchell J., Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol. 1993 Oct;2(4):155–162. [PubMed] [Google Scholar]
  6. Deckers P. J. Axillary dissection in breast cancer: when, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol. 1991 Dec;48(4):217–219. doi: 10.1002/jso.2930480402. [DOI] [PubMed] [Google Scholar]
  7. Doerr R. J., Abdel-Nabi H., Baker J. M., Steinberg S. Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3. Arch Surg. 1990 Dec;125(12):1601–1605. doi: 10.1001/archsurg.1990.01410240083016. [DOI] [PubMed] [Google Scholar]
  8. Fisher B., Redmond C., Fisher E. R., Bauer M., Wolmark N., Wickerham D. L., Deutsch M., Montague E., Margolese R., Foster R. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985 Mar 14;312(11):674–681. doi: 10.1056/NEJM198503143121102. [DOI] [PubMed] [Google Scholar]
  9. Girling A., Bartkova J., Burchell J., Gendler S., Gillett C., Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer. 1989 Jun 15;43(6):1072–1076. doi: 10.1002/ijc.2910430620. [DOI] [PubMed] [Google Scholar]
  10. Goldenberg D. M., Larson S. M. Radioimmunodetection in cancer identification. J Nucl Med. 1992 May;33(5):803–814. [PubMed] [Google Scholar]
  11. Granowska M., Biassoni L., Carroll M. J., Howell R., Mather S. J., Ellison D., Granowski A., Britton K. E. Breast cancer 99mTc SM3 radioimmunoscintigraphy. Acta Oncol. 1996;35(3):319–321. doi: 10.3109/02841869609101648. [DOI] [PubMed] [Google Scholar]
  12. Granowska M., Britton K. E., Mather S. J., Lowe D. G., Ellison D., Bomanji J., Burchell J., Taylor-Papadimitriou J., Hudson C. R., Shepherd J. H. Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer. Eur J Nucl Med. 1993 Jun;20(6):483–489. doi: 10.1007/BF00175160. [DOI] [PubMed] [Google Scholar]
  13. Granowska M., Jass J. R., Britton K. E., Northover J. M. A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake. Int J Colorectal Dis. 1989;4(2):97–108. doi: 10.1007/BF01646868. [DOI] [PubMed] [Google Scholar]
  14. Granowska M., Mather S. J., Jobling T., Naeem M., Burchell J., Taylor-Papadimitriou J., Shepherd J., Britton K. E. Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int J Biol Markers. 1990 Apr-Jun;5(2):89–96. doi: 10.1177/172460089000500208. [DOI] [PubMed] [Google Scholar]
  15. Granowska M., Nimmon C. C., Britton K. E., Crowther M., Mather S. J., Slevin M. L., Shepherd J. H. Kinetic analysis and probability mapping applied to the detection of ovarian cancer by radioimmunoscintigraphy. J Nucl Med. 1988 May;29(5):599–607. [PubMed] [Google Scholar]
  16. Harris J. R., Osteen R. T. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat. 1985;5(1):17–21. doi: 10.1007/BF01807645. [DOI] [PubMed] [Google Scholar]
  17. Khalkhali I., Mena I., Jouanne E., Diggles L., Venegas R., Block J., Alle K., Klein S. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994 May;178(5):491–497. [PubMed] [Google Scholar]
  18. Kim E. E., Corgan R. L., Casper S., Primus F. J., Spremulli E., Estes N., Goldenberg D. M. Axillary lymphoscintigraphy by radioimmunodetection of carcinoembryonic antigen in breast cancer. J Nucl Med. 1979 Dec;20(12):1243–1250. [PubMed] [Google Scholar]
  19. Krag D. N., Weaver D. L., Alex J. C., Fairbank J. T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993 Dec;2(6):335–340. doi: 10.1016/0960-7404(93)90064-6. [DOI] [PubMed] [Google Scholar]
  20. Massuger L. F., Kenemans P., Claessens R. A., Verheijen R. H., Schijf C. P., Strijk S. P., Poels L. G., van Hoesel R. G., Corstens F. H. Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody. J Nucl Med. 1990 Nov;31(11):1802–1810. [PubMed] [Google Scholar]
  21. Mather S. J., Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med. 1990 May;31(5):692–697. [PubMed] [Google Scholar]
  22. Nieweg O. E., Kim E. E., Wong W. H., Broussard W. F., Singletary S. E., Hortobagyi G. N., Tilbury R. S. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer. 1993 Jun 15;71(12):3920–3925. doi: 10.1002/1097-0142(19930615)71:12<3920::aid-cncr2820711220>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  23. Palmedo H., Grünwald F., Bender H., Schomburg A., Mallmann P., Krebs D., Biersack H. J. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med. 1996 Aug;23(8):940–946. doi: 10.1007/BF01084368. [DOI] [PubMed] [Google Scholar]
  24. Schatten C., Barrada M., Mandeville R., Enzelsberger H., Angelberger P., Czerwenka K., Kubista E., Pateisky N. Combined use of 123I-labelled BCD-F9 and 4C4 monoclonal antibody with dissimilar specificity for breast cancer: implication for the detection limit of immunolymphoscintigraphy in the assessment of axillary lymph node metastases. Nucl Med Commun. 1994 Jun;15(6):422–429. doi: 10.1097/00006231-199406000-00005. [DOI] [PubMed] [Google Scholar]
  25. Silverstein M. J., Gierson E. D., Waisman J. R., Senofsky G. M., Colburn W. J., Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer. 1994 Feb 1;73(3):664–667. doi: 10.1002/1097-0142(19940201)73:3<664::aid-cncr2820730326>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  26. Tjandra J. J., Russell I. S., Collins J. P., Andrews J. T., Lichtenstein M., Binns D., McKenzie I. F. Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer. Cancer Res. 1989 Mar 15;49(6):1600–1608. [PubMed] [Google Scholar]
  27. Wahl R. L., Cody R. L., Hutchins G. D., Mudgett E. E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991 Jun;179(3):765–770. doi: 10.1148/radiology.179.3.2027989. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES